ArticlePLOS digital health2026
Digital measurement of ocular microtremor in Parkinson's Disease: Analytical and clinical validation.
Article in PLOS digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular microtremor (OMT) is an involuntary fixational eye movement linked to brainstem activity. OMT is thought to have a mean frequency range of 70-90 Hz in healthy adults. Previous research suggests OMT may be reduced in neurological diseases like Parkinson's Disease. Historically, OMT has been measured invasively in specialist laboratories using lengthy and expensive protocols. Developments now allow for OMT measurement quickly and non-invasively using hand-held technology (i.e., iTremor ONE). This pilot study aimed to examine the analytical and clinical validation of OMT measurement via the iTremor ONE in people with Parkinson's Disease (PwPD). 33 PwPD and 31 age matched healthy controls participated in this study. For analytical validation, 22 PwPD completed a test re-test reliability assessment of OMT measurement, assessed using interclass correlation coefficients (ICC). For clinical validation, OMT frequency in PwPD (n = 33) was compared to controls. Correlations were explored with demographics and clinical scales. Additionally, 24 PwPD were tested 'OFF' (12hr withdrawal) and 'ON' their anti-Parkinson's (dopaminergic) medication to compare OMT response to a known intervention. The iTremor ONE demonstrated excellent test-retest reliability (ICC > 0.9) for measuring OMT frequency in PwPD. Mean OMT frequency was significantly lower in PwPD (63.78 ± 4.82 Hz) compared to controls (69.44 ± 6.47 Hz, p < .001), with good discriminative ability (AUC 0.75-0.77). OMT frequency correlated with age in both groups and with specific motor features (speech, facial expression, gait) in PwPD. No significant differences in OMT frequency were observed between 'OFF' and 'ON' dopaminergic medication states. This is the first study to demonstrate that a non-invasive hand-held device can reliably measure OMT in PwPD and presents OMT analytical and clinical validation evidence. OMT frequency may provide a supporting measure for diagnosis or screening. Further research is required to understand the neural mechanisms underpinning OMT in PwPD and the role it could play in clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.